According to Novartis, the manufacturer of Kymriah (tisagenlecleucel), the cancer therapy will cost $475,000 for one treatment course. Kymriah is a chimeric antigen receptor T cell (CAR-T) therapy for use in pediatric and young adult patients (up to age 25) with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL).
Subscribe to receive email notifications whenever new articles are published.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include IBM Watson Micromedex (updated Dec 6th, 2018), Cerner Multum™ (updated Dec 7th, 2018), Wolters Kluwer™ (updated Dec 5th, 2018) and others. To view content sources and attributions, please refer to our editorial policy.